Home

Biotron Limited

ASX Code

BIT

Sector

Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre

https://www.biotron.com.au/investor-centre/

Website

https://www.biotron.com.au/

About

Biotron Limited – Developing a new class of antiviral therapies

Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.

News

Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy